6-甲基灯心草二酚 | 62023-90-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 中文名称: 6-甲基灯心草二酚
• 中文别名: 灯心草酚
• 英文名称: juncusol
• 英文别名: 2,7-dihydroxy-1,6-dimethyl-5-vinyl-9,10-dihydrophenanthrene；5-ethenyl-1,6-dimethyl-9,10-dihydrophenanthrene-2,7-diol
• CAS: 62023-90-9
• 化学式: C₁₈H₁₈O₂
• 分子量: 266.34
• InChiKey: XNVMKPYDOHZJLR-UHFFFAOYSA-N

物化性质

• 沸点：
  503.8±50.0 °C(Predicted)
• 密度：
  1.202±0.06 g/cm3(Predicted)
• LogP：
  5.120 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2906299090

反应信息

• 作为反应物：
  描述：

  6-甲基灯心草二酚 、 硫酸二甲酯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 juncusol dimethyl ether
  参考文献：
  名称：

  Action of antialgal compounds fromJuncus effusus L. onSelenastrum capricornutum

  摘要：

  Twenty-nine free and glucosylated dihydrophenanthrenes and tetrahydropyrenes isolated from Juncus effusus have been tested against the unicellular green alga Selenastrum capricornutum. The free compounds showed a strong inhibitory activity, while the glucosides were inactive or had a slight stimulating effect on growth. Tetrahydropyrene 33, obtained by hydrolysis of the natural beta-glucosides 29 and 30 or by hemisynthesis from 1, is the most active compound, causing 90% inhibition of the growth at 2.5 x 10(-5) M concentration. Synthetic ai-glucosides 28, 31, and 32 showed comparable activity to those of 29 and 30.

  DOI：

  10.1007/bf02033657
• 作为产物：
  描述：

  1-(3,4-二氢-6-甲氧基-5-甲基-1-(2-丙烯基)-2-萘基)-3-丁炔-3-酮 在 collidine p-toluenesulfonate 、 lithium methanethiolate 作用下， 以 六甲基磷酰三胺 为溶剂， 反应 3.0h， 生成 6-甲基灯心草二酚
  参考文献：
  名称：

  juncusol的新型合成

  摘要：

  Juncusol（7）已通过新颖的电环化工艺从已知的β-四氢萘酮衍生物9开始制备。

  DOI：

  10.1016/s0040-4039(00)79645-6

文献信息

• Enynones in Organic Synthesis. 8. Synthesis of the Antimicrobial-Cytotoxic Agent Juncusol and Members of the Effusol Class of Phenols
  作者：Peter A. Jacobi、Joseph I. Kravitz、Wanjun Zheng

  DOI：10.1021/jo00107a017

  日期：1995.1

  Two new syntheses of phenols have been developed which have been utilized in an efficient preparation of the antimicrobial-cytotoxic agent juncusol (22) and several members of the effusol (23) class of phenols. These results complement our earlier studies with enynones of type 42 and provide for the highly efficient conversion of 42 to either methylenecyclopentenones 45 or phenols of type 47 or 54 with virtually 100% selectivity.
• Regiospecific total synthesis of juncusol
  作者：Dale L. Boger、Michael D. Mullican

  DOI：10.1021/jo00195a034

  日期：1984.10
• COMPOSITIONS COMPRISING CO-CRYSTALS OF STILBENOIDS AND CANNABINOIDS
  申请人：NEUTRISCI INTERNATIONAL INC.

  公开号：US20200397744A1

  公开（公告）日：2020-12-24

  A composition for oral administration comprising a cannabinoid in combination with a stilbenoid or derivative thereof and a solubility enhancing agent is described. Oral dosage forms, in the form of dissolvable tablet or capsule with enhanced bioavailability and processes for preparing them are also disclosed. The processes include lyophilisation of the cannabinoid powder or cannabinoid-stilbenoid co-crystals to form a powder which is pressed into tablets. The powder may be generated from the co-crystals of the cannabinoid with pterostilbene or the powder may be formed by subsequently mixing the lyophilized cannabinoid with the stilbenoid before forming the tablet.
• US4873349A
  申请人：——

  公开号：US4873349A

  公开（公告）日：1989-10-10
• [EN] COMPOSITIONS COMPRISING CO-CRYSTALS OF STILBENOIDS AND CANNABINOIDS<br/>[FR] COMPOSITIONS COMPRENANT DES CO-CRISTAUX DE STILBÉNOÏDES ET DE CANNABINOÏDES
  申请人：NEUTRISCI INT INC

  公开号：WO2019153088A1

  公开（公告）日：2019-08-15

  A composition for oral administration comprising a cannabinoid in combination with a stilbenoid or derivative thereof and a solubility enhancing agent is described. Oral dosage forms, in the form of dissolvable tablet or capsule with enhanced bioavailability and processes for preparing them are also disclosed. The processes include lyophilisation of the cannabinoid powder or cannabinoid-stilbenoid co-crystals to form a powder which is pressed into tablets. The powder may be generated from the co-crystals of the cannabinoid with pterostilbene or the powder may be formed by subsequently mixing the lyophilized cannabinoid with the stilbenoid before forming the tablet.